Status:
COMPLETED
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
Lead Sponsor:
Organon and Co
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-79 years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.
Eligibility Criteria
Inclusion
- Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL
- Patient willing to be on a low-cholesterol diet
Exclusion
- Pregnant or lactating women or intending to become pregnant
- Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet
- Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin
- Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
1220 Patients enrolled
Trial Details
Trial ID
NCT00271817
Start Date
December 1 2005
End Date
February 1 2008
Last Update
May 16 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.